**Core tip:** In the present study, we identified a total of 42 senescence-associated genes (SAGs) and found seven of them were significantly downregulated in senescent cells and upregulated in HCC tissues. By using the least absolute shrinkage and selection operator, we constructed a seven-SAG signature that could predict the overall survival (OS) of hepatocellular carcinoma. This seven-SAG signature was further validated and developed in another independent dataset from The Cancer Genome Atlas project. Moreover, our risk score system showed better utility in predicting the OS than classic serum biomarker α-fetoprotein.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) becomes the third leading cause of cancer deaths worldwide, with approximately 80% of mortalities occurring within 5 years\[[@B1],[@B2]\]. During the past decades, great effects have been made to improve the management of HCC. As more and more HCCs are diagnosed at an early stage, treatment efficacy is greatly improved\[[@B3]\]. Whereas, deaths caused by HCC always occur when patients undergo treatment and the clinical outcome of HCC patients is still poor\[[@B4]\]. Moreover, HCC is an extremely heterogeneous disease, which must be monitored for high-risk patients with poor clinical outcomes and adopt effective treatments to improve patient survival\[[@B5]\]. Traditional serum markers, especially alpha-fetoprotein (AFP), have been the most common prognostic indicators in clinic. However, they significantly depend on tumor burden, which limits their value in diagnosing early stage tumors. Therefore, identifying novel prognostic biomarkers contributes to early diagnosis and reducing HCC mortality.

Cellular senescence is considered to be a response of a proliferating somatic cell to stress and damage derived from both exogenous and endogenous sources, and persistent DNA damage is the most common cause\[[@B6]\]. It is characterized as a permanent cell cycle arrest\[[@B7]\]. Cellular senescence has been deemed as a mechanism of limited cell division due to progressive telomere shortening\[[@B8]\]. In cancer cells, there exists telomere-independent senescence due to their activation of telomerase. For instance, numerous studies found that RAS activation could induce cellular senescence in many cancer cell types. Both telomere-dependent and -independent pathways induced senescence by inducing a DNA damage response. Recently, it has been demonstrated that hepatocytes escaping from senescence played a key role in hepatic carcinogenesis and HCC progression\[[@B9],[@B10]\]. During the senescence process, a large number of genes are expressed differentially. Hence, it is reliable to focus on senescence associated genes (SAGs) as a novel approach in cancer diagnosis and monitor.

Bearing this in mind, we first identified the SAGs by analyzing the genome profiling data derived from two types of senescent cells, replicative senescence (RS) and oncogene-induced senescence (OIS). Next, we investigated the prognostic value of several candidate SAGs in predicting survival of HCC by multistep comparisons. Finally, we validated that the candidate SAGs were superior to classic serum biomarker AFP in predicting the OS in HCC cohort retrieved from the Cancer Genome Atlas (TCGA). As far as we know, the study is the first to investigate the expression patterns of SAGs between senescence and HCC and their association with clinical prognosis of Asian patients with HCC.

MATERIALS AND METHODS
=====================

Data sources and processing
---------------------------

Two genomic profiling datasets of RS cells (GSE19018 and GSE36640), three datasets of OIS cells (GSE19864, GSE40349, and GSE60652), and one HCC dataset (GSE14520) were obtained from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>). RMA algorithm was performed to normalize and transform all the selected data from GEO to expression values in the R environment (v3.5.1). Among them, GSE14520 (based on GPL3921 platform) enrolled 209 HCC patients with survival data. An independent HCC cohort derived from TCGA database (TCGA-LIHC) was used as a validation group. The level 3 RNAseqv2 data and clinical data were derived from the TCGA data portal. A total of 370 HCC samples were included.

Differential gene expression analysis
-------------------------------------

Differentlly expressed genes (DEGs) were calculated in RS and OIS cell models, respectively. Only fold change (FC) ≥ 1.5 and *q*-value \< 0.05 were considered statistically significant. Then, we picked up the overlapped significantly expressed genes in the two senescent models. Venn diagram was carried out using Venny 2.1.0. Moreover, the expression levels of candidate genes were plotted and analyzed by the *t*-test in GSE14520 and TCGA-LIHC cohorts.

Prognostic model development
----------------------------

A prognostic model was created by the seven-SAG signature according to least absolute shrinkage and selection operator (LASSO) analysis. LASSO is one of the most popular approaches for sparse linear regression\[[@B11]\]. "Almnet" package was carried out based on a series of λ in the R environment (v3.5.1)\[[@B12]\] and the coefficients of each gene in the risk score system were generated. We got a risk score for every patient based on their own expression levels of the seven genes after the LASSO regression analysis.

Survival analysis
-----------------

Univariate and multivariate survival analyses were carried out and further multivariate COX regression analysis only included variables with *P* \< 0.05. All tests were carried out using SPSS (version 24.0; Chicago, United States). Kaplan-Meier curves were generated using GraphPad Prism 7.0. Comparisons between different subgroups were performed by the Log-Rank test. Patients are divided into high- and low- risk groups by the median.

Time-dependent receiver operating characteristic curve (ROC) analysis
---------------------------------------------------------------------

ROC curve is extended to evaluate biomarker's accuracy of discriminating binary outcomes\[[@B13]\]. Individuals with a high risk of developing the disease later may be disease-free in earlier life and their markers' value may change from baseline during follow-up. Therefore, time-dependent ROC curve analysis is more appropriate and outperforms the conventional method adopted for handling censored biomarker data. In this study, the time-dependent ROC curve analysis was performed with "survival ROC" package (R version 3.5.1). The prognostic performance was evaluated at 1, 3, and 5 years to compare the predictive accuracy and sensitivity of different prognostic models.

Statistical analysis
--------------------

The chi-square test was carried out to discover the relationship between gene expression and clinical parameters. Unpaired student's *t*-test was used to analyze the difference of gene expression in HCC patients of different features. *P \<* 0.05 was considered statistically different. Statistical analyses were performed using IBM SPSS Statistics software program version 24.0 (IBM Corp, NY, United States).

RESULTS
=======

Identification of SAGs using different senescent models
-------------------------------------------------------

The overall workflow of the data processing is presented in Figure [1A](#F1){ref-type="fig"}. To identify SAGs, we first integrated five different microarray profiles (GSE19018, GSE36640, GSE19864, GSE40349, and GSE60652). All datasets used in the present study were normalized before analysis. The relative expression of all samples pre- and post-normalization is shown in Figure [1B](#F1){ref-type="fig"}. Next, we screened the DEGs, which were identified as FC ≥ 1.5 and *q*-value \< 0.05 (senescent *vs* proliferating cells), in RS and OIS models, respectively. A total of 781 up-regulated and 739 down-regulated genes were selected in the RS model, and 103 up-regulated and 288 down-regulated genes in the OIS model (Figure [2A](#F2){ref-type="fig"}). By overlapping the two DEG lists, 42 common differentially expressed genes (35 downregulated and only 7 upregulated genes) were selected as SAGs (Figure [2B](#F2){ref-type="fig"}) and the expression levels of these genes in RS and OIS models are presented as a heat map in Figure [2C](#F2){ref-type="fig"}.

![Data sources and processing. A: Flowchart describing the process used to generate differentially expressed senescence-associated genes; B: The relative expression in all samples pre- and post-normalization.](WJG-25-1715-g001){#F1}

![Expression of differentially expressed genes in senescent cells. A: The differentially expressed genes were identified in replicative senescence (RS) and oncogene-induced senescence (OIS) models. There were 781 up-regulated and 739 down-regulated genes selected using the RS model, and 103 up-regulated and 288 down-regulated genes selected using the OIS model; B: Overlapping the two lists, 42 common differentially expressed genes were selected as senescence associated genes; C: The expression levels of 42 genes are presented as a heat map in RS and OIS models. DEGs: Differentially expressed genes; RS: Replicative senescence; OIS: Oncogene-induced senescence; SAGs: Senescence associated genes; FC: Fold change; LASSO: Least absolute shrinkage and selection operator.](WJG-25-1715-g002){#F2}

Construction of a risk score system
-----------------------------------

To obtain a prognostic SAG signature for HCC survival prediction, we first performed univariate COX regression analysis to evaluate the prognostic value of each candidate gene. And we found that all seven genes (*CEP55*, *MCM7*, *CDC45*, *MCM5*, *KIF18B*, *CIT*, and *EZH2*) were proved to be risk factors for HCC patients. Next, we screened the expression pattern of the above 7 candidate genes in HCC cohorts. Intriguingly, seven downregulated genes in senescent cells, were significantly upregulated in HCC tissues in both discovery and validation groups, with a *P*-value \< 0.0001 (Figure [3](#F3){ref-type="fig"}). We then developed a risk score formula based on these seven SAGs using the LASSO method: Risk score = (0.243 × relative expression value of *KIF18B*) + (0.274 × relative expression value of *CEP55*) + (0.282 × relative expression value of *CIT*) + (0.266 × relative expression value of *MCM7*) + (0.678 × relative expression value of *CDC45*) + (0.175 × relative expression value of *EZH2*) + (0.536 × relative expression value of *MCM5*). In this risk score system, the contribution of every gene to the risk score model was weighted by absolute value of coefficients. Every patient would get a risk score based on the expression of the seven SAGs of themselves.

![Expression of the seven candidate genes in hepatocellular carcinoma and normal liver tissues. A: *MCM5*; B: *MCM7*; C: *EZH2*; D: *CDC45*; E: *CIT*; F: *KIF18B*; G: *CEP55*. Seven senescence associated genes, which were downregulated in senescent cells, were shown to be upregulated in hepatocellular carcinoma tissues in both discovery and validation cohorts. *P* \< 0.0001 for all.](WJG-25-1715-g003){#F3}

Validation of the seven-SAG signature for prognosis
---------------------------------------------------

To confirm the potentiality of the seven-SAG prognostic model, Kaplan-Meier curve was carried out to evaluate the association between the overall survival (OS) and our gene signature in discovery (GSE14520) and validation (TCGA-LIHC) cohorts. The whole group was divided into the high- and low-risk subgroups according to the median of all patients' risk scores. In the discovery cohort, with the increase in the risk score, the expression of all the seven genes was increasing, and the death events accumulated (Figure [4A](#F4){ref-type="fig"}). The patients in the high-risk subgroup had a 1.92-fold higher death risk than the low subgroup \[hazard ratio (HR), 95% confidence interval (CI) = 1.92, 1.16-3.19; log-rank *P* value = 0.011\] (Figure [4B](#F4){ref-type="fig"}). We then tempted to test these findings in the validation cohort (TCGA-LIHC) (Figure [4C](#F4){ref-type="fig"}). Similar to the findings obtained from the discovery cohort, patients in the high-risk group \[median survival time (MST) = 46.6 m\] had significantly shorter OS time than patients with a low-risk score (MST = 70.5 m) \[HR (95%CI) = 1.80 (1.27-2.54), log-rank *P* value = 0.001\] (Figure [4D](#F4){ref-type="fig"}). Interestingly, when we analyzed the data in the Asian population, we observed a highly significant association between the seven-SAG signature and OS. The majority of death events occurred in the high-risk group (Figure [4E](#F4){ref-type="fig"}). Asian HCC patients with a high-risk score were shown to have a \> 5-fold increased death risk than low-risk patients \[HR (95%CI) = 5.81 (3.20-10.54), log-rank *P* value \< 0.0001\]. The MST of the high-risk subgroup was only 60% of that of the low-risk group (MST = 21.6 m *vs* 91.7 m) (Figure [4F](#F4){ref-type="fig"}). In order to investigate the prognostic value of the risk score system in different patient groups with different characteristics, we performed univariate/multivariate Cox regression analysis of clinicopathologic factors associated with OS in the discovery and validation cohorts. From the Cox regression results, both the seven-SAG signature and serum AFP level were confirmed to be independent risk factors of OS in the two cohorts (Table [1](#T1){ref-type="table"}).

###### 

Univariate/multivariate Cox regression analysis of clinicopathologic factors associated with overall survival in GSE14520 and The Cancer Genome Atlas cohorts

  **Variable**               **Discovery cohort**   **Validation cohort-Asian only**                                                                                                                                                     
  -------------------------- ---------------------- --------------------------------------- ------------------ --------------------------------------- ------------------- ------------------------------------------ ------------------ ------------------------------------------
  Gender (male/female)       1.36 (0.55-3.40)       0.507                                   \-                 \-                                      0.89 (0.43-1.86)    0.755                                      \-                 \-
  Age (\> 60/≤ 60 yr)        1.06 (0.57-2.00)       0.851                                   \-                 \-                                      1.21 (0.66-2.24)    0.541                                      \-                 \-
  Cirrhosis (yes/no)         3.09 (0.76-12.65)      0.117                                   \-                 \-                                      2.44 (1.56-3.85)    \< 0.001[a](#T1FN1){ref-type="table-fn"}   1.67 (1.04-2.70)   0.034[a](#T1FN1){ref-type="table-fn"}
  AFP (\> 300/≤ 300 ng/mL)   2.30 (1.37-3.86)       0.002[a](#T1FN1){ref-type="table-fn"}   2.26 (1.38-3.69)   0.001[a](#T1FN1){ref-type="table-fn"}   3.70 (2.13-6.25)    \< 0.001[a](#T1FN1){ref-type="table-fn"}   2.13 (1.30-3.57)   0.003[a](#T1FN1){ref-type="table-fn"}
  Risk score (high/low)      1.93 (1.15-3.23)       0.012[a](#T1FN1){ref-type="table-fn"}   1.99 (1.19-3.34)   0.009[a](#T1FN1){ref-type="table-fn"}   5.91 (2.74-12.76)   \< 0.001[a](#T1FN1){ref-type="table-fn"}   4.22 (1.89-9.41)   \< 0.001[a](#T1FN1){ref-type="table-fn"}

Statistically significant. HR: Hazard ratio; CI: Confidence interval; AFP: Alpha-fetoprotein.

![The seven-senescence associated gene signature is associated with overall survival in the discovery and validation cohorts. A: The heat map of the expression of seven genes and patients' death status in the discovery cohort; B: Kaplan-Meier survival curves plotted to estimate the overall survival probabilities for the low-risk *vs* high-risk group in the discovery cohort; C: The heat map of the expression of seven genes and patients' death status in the validation cohort; D: Kaplan-Meier survival curves plotted to estimate the overall survival probabilities for the low-risk *vs* high-risk group in the validation cohort; E: The heat map of the expression of seven genes and patients' death status in the validation cohort-Asian only subgroup; F: Kaplan-Meier survival curves plotted to estimate the overall survival probabilities for the low-risk *vs* high-risk group in the validation cohort-Asian only subgroup. HR: Hazard ratio; CI: Confidence interval.](WJG-25-1715-g004){#F4}

Comparison of the seven-SAG signature and serum AFP in predicting OS
--------------------------------------------------------------------

To assess the prognostic accuracy of the seven-SAG signature, we performed time-dependent ROC analysis of 1-, 3-, and 5-year OS of the validation cohort. The area under the curve (AUC) of the seven-SAG signature model indicated an acceptable predictive accuracy, which is superior to AFP, a widely used traditional serum marker, at 1 year (our seven-gene model AUC = 0.708, serum AFP level AUC = 0.606) (Figure [5A](#F5){ref-type="fig"}), 3 years (our seven-gene model AUC = 0.699, serum AFP level AUC = 0.568) (Figure [5B](#F5){ref-type="fig"}) as well as 5 years (our seven-gene model AUC = 0.678, serum AFP level AUC = 0.604) (Figure [5C](#F5){ref-type="fig"}). These results indicated the validation of the prognostic signature.

![Comparison of the seven-senescence associated gene signature and α-fetoprotein in predicting overall survival of hepatocellular carcinoma patients. To assess the prognostic accuracy of the seven-senescence associated gene signature and serumα-fetoprotein level, time-dependent receiver operating characteristic curve analysis was conducted for 1-, 3-, and 5-year overall survival (OS). A: 1-year OS; B: 3-year OS; C: 5-year OS. AUC: Area under the curve; AFP: Alpha-fetoprotein; OS: Overall survival.](WJG-25-1715-g005){#F5}

Stratified analysis of the seven-SAG signature for prognosis prediction
-----------------------------------------------------------------------

Stratified analyses based on the clinical characteristics were carried out to identify the suitable Asian patient groups for the seven-SAG signature (Table [2](#T2){ref-type="table"}). In the elderly population, patients with a high-risk score had a more than 3-fold increased risk of death than the low-risk group (Figure [6A](#F6){ref-type="fig"}-C). These results suggested that our seven-SAG signature was more applicable to the HCC patients with older age in predicting OS.

###### 

Stratified analysis of overall survival in GSE14520 and The Cancer Genome Atlas cohorts

  **Variable**   **Discovery cohort**   **Validation cohort-Asian only**                                                                       
  -------------- ---------------------- ---------------------------------- --------------------------------------- ------- ------------------- ------------------------------------------
  Overall        76/75                  1.92 (1.16-3.19)                   0.011[a](#T2FN1){ref-type="table-fn"}   79/78   5.81 (3.20-10.54)   \< 0.001[a](#T2FN1){ref-type="table-fn"}
  Gender                                                                                                                                       
  Male           69/67                  2.15 (1.27-3.64)                   0.004[a](#T2FN1){ref-type="table-fn"}   62/61   5.18 (2.66-10.10)   \< 0.001[a](#T2FN1){ref-type="table-fn"}
  Female         7/8                    0.60 (0.10-3.47)                   0.569                                   17/17   9.63 (2.59-35.77)   0.009[a](#T2FN1){ref-type="table-fn"}
  Age (yr)                                                                                                                                     
  ≤ 60           64/60                  1.70 (0.97-2.98)                   0.064                                   53/52   5.22 (2.49-10.97)   \< 0.001[a](#T2FN1){ref-type="table-fn"}
  \> 60          12/15                  3.19 (1.00-10.20)                  0.045[a](#T2FN1){ref-type="table-fn"}   26/26   6.47 (2.38-17.59)   \< 0.001[a](#T2FN1){ref-type="table-fn"}
  Cirrhosis                                                                                                                                    
  Yes            70/69                  1.93 (1.15-3.22)                   0.012[a](#T2FN1){ref-type="table-fn"}   17/24   3.50 (0.66-18.47)   0.122
  No             6/6                    1.73 (0.10-30.65)                  0.695                                   11/28   0.98 (0.19-5.00)    0.979
  AFP (ng/mL)                                                                                                                                  
  ≤ 300          40/39                  1.73 (0.77-3.87)                   0.179                                   34/55   2.94 (1.01-8.57)    0.036[a](#T2FN1){ref-type="table-fn"}
  \> 300         34/34                  2.11 (1.09-4.08)                   0.025[a](#T2FN1){ref-type="table-fn"}   16/16   2.65 (0.60-11.66)   0.226

Statistically significant. HR: Hazard ratio; CI: Confidence interval; AFP: Alpha-fetoprotein.

![Association between the seven-senescence associated gene signature and overall survival in the elderly age subgroup. Kaplan-Meier survival curves were plotted to estimate the overall survival probabilities for the low-risk *vs* high-risk group. A: Discovery group; B: Validation group; C: Combination of discovery group and validation group. HR: Hazard ratio; CI: Confidence interval.](WJG-25-1715-g006){#F6}

DISCUSSION
==========

In this study, we first identified 42 overlapped DEGs using the RS and OIS models. Among them, seven downregulated genes in senescent cells, *KIF18B*, *CEP55*, *CIT*, *MCM7*, *CDC45*, *EZH2*, and *MCM5*, were shown to be upregulated in HCC tissues and selected to construct a prognostic model. The seven-SAG signature was shown to be associated with OS in both discovery and validation cohorts. Stratified analysis showed that our seven-SAG signature was significantly associated with OS in elderly Asian patients. Moreover, time-dependent ROC analysis showed a favorable prognostic value of our seven-SAG signature when compared with serum AFP.

The cellular senescence is considered an aging hallmark. With the increase in age, the number of senescent cells is increasing. Cellular senescence is widely considered to be an anti-tumor mechanism. Studies have shown that a source of stress that triggers liver senescence is chronic inflammation, which causes damage to liver cell regeneration. Importantly, abrogation of senescence leads to aggressive HCC development\[[@B14]\]. In the present study, we found that the HCC patients carrying high expression of seven SAGs had a shorter OS time. Stratified results further suggested the seven-SAG signature was more applicable to the elderly HCC patients. The potential explanation might be that due to the increasing number of senescent cells, the expression of the seven-SAG signature is decreased, while its high expression indicates a higher proliferation rate and poorer OS.

It has been widely accepted that senescence pathways are collectively at the level of activation of CDKIs, which play pivotal roles in regulating the cell cycle progression. Of the seven genes, *KIF18B*, a member of the kinesin-8 subfamily, is involved in cell cycle process\[[@B15]\] and acts as an oncogene in cervical cancer\[[@B16]\]. *CEP55*, also known as c10orf3 and FLJ10540, promotes tumorigenesis and regulates stemness in various cancers, such as lung adenocarcinoma\[[@B17]-[@B19]\]. *CIT* (Serine/threonine kinase 21) encoding a serine/threonine protein kinase, is a downstream effector of Rho family GTPases and participates in cell cycle regulation. Liu et al\[[@B20]\] and Xu et al\[[@B21]\] have demonstrated that *CIT* is up-regulated in HCC and regulates the G2/M transition in rat hepatocytes. EZH2 is a subunit of polycomb repressive complex 2 (PRC2), a protein complex that induces epigenetically silencing of genes\[[@B22]\]. And it has been reported that several lncRNAs are able to regulate gene transcription by binding to PRC2\[[@B23],[@B24]\].

In most eukaryotes, the MCM complex consists of six highly conserved MCM proteins, namely *MCM2--7*, which functions as a replicative DNA helicase to unwind the DNA duplex template during DNA replication\[[@B25]\]. Recent evidence has demonstrated that several MCM proteins are tightly associated with tumorigenesis\[[@B26]-[@B28]\]. The MCM2-7 hexamer complexes with CDC45 and the hetero-tetrameric GINS complex, the Cdc45-Mcm2-7-GINS (CMG) complex, function as a potential target for cancer treatment and CDC45 interacts with MCM2\[[@B29]\]. Furthermore, our previous study showed that MCM7 promotes cancer progression through cyclin D1-dependent signaling in HCC\[[@B30]\]. Three members of CMG complex, *MCM5*, *MCM7*, and *CDC45*, were included in the risk formula. This evidence indicated that more attention should be focused on the pro-oncogenic mechanisms of senescence escape of HCC cells.

Our study showed that AFP was an independent risk factor for HCC patients. AFP is often expressed at high levels in most HCC patients and is considered a reliable clinical tumor biomarker. As a classic serum biomarker, AFP was found to be associated with prognosis in HCC patients\[[@B31],[@B32]\]. Park et al\[[@B33]\] reported that AFP combined with PIVKA-II were useful in predicting survival in the radiological treatment of locally advanced HCC. Jiang et al\[[@B34]\] also found that preoperative AFP and fibrinogen showed a predictive power for recurrence of HCC after liver transplantation. Here, our study demonstrated that the seven-SAG signature model was superior to serum AFP level and more applicable in predicting OS of HCC patients with older age. The above findings suggested a potential clinical application of the seven-SAG signature in HCC patients.

However, there are some limitations in our study. First, the samples for screening SAG were small, which might cause false positive results. Second, we constructed the risk score system merely based on the gene expression levels, rather than the other genetic events that probably have an effect on the initiation and progression of cancer. Third, patients in the discovery cohort were from Asia, thus, the risk score system was established based on an Asian background. And further stratified analysis in the validation cohort also showed that this model was more suitable for Asian patients. Hence, our HCC prognostic signature still needs to be validated in a larger group of patients from various populations.

In conclusion, we constructed and confirmed a prognostic risk score system comprised of seven SAGs. The seven-SAG signature could be a potential predictor for OS, particularly in elderly Asian HCC patients. Our data provide new promising evidence on prediction biomarkers and targeted therapy for HCC.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Hepatocellular carcinoma (HCC) is a common malignancy that remains a serious cause of death worldwide. Recently, molecular markers and prognostic models have been used to improve the diagnosis and treatment of HCC, but few can be applied clinically. Currently, bioinformatics technology has been used for data mining in large public databases. The abundant sample size in the public database can make up for the shortcomings of small samples in real hospitals and help to seek for a more accurate and applicable prognostic model for HCC.

Research motivation
-------------------

Researchers have been making efforts to find molecular markers or prognostic models that can effectively predict the prognosis of HCC. Senescence is a cell cycle arrest caused by stress in cells, but the cells are still alive. Studies have shown that the proportion of senescent cells in tissues of patients with cirrhosis increases, but a considerable number of patients with cirrhosis can develop liver cancer, and its specific molecular mechanism has rarely been reported.

Research objectives
-------------------

By analyzing the database of two cellular senescence models from Gene Expression Omnibus, we screened for senescence-associated genes and validated these genes in the liver cancer databases (GSE14520 and TCGA-LIHC). Then, we constructed an HCC prognostic model and evaluate its prognostic accuracy.

Research methods
----------------

Senescence-associated genes (SAGs) were identified using R package "limma". The latest statistical algorithm-the least absolute shrinkage and selection operator (LASSO) was applied to create our prognostic model. Time-dependent receiver operating characteristic (ROC) curves were used to compare the prognostic accuracy between the seven-SAG signature and serum α-fetoprotein.

Research results
----------------

The prognostic model for predicting the overall survival (OS) of HCC was constructed by LASSO, consisting of the seven senescence-associated genes (SAGs) (*KIF18B*, *CEP55*, *CIT*, *MCM7*, *CDC45*, *EZH2*, and *MCM5*). All seven SAGs were highly expressed in HCC and proliferating cells, while lowly expressed in normal tissues and senescent cells. Survival analysis showed that our seven-SAG characteristics are closely related to OS, especially in Asian populations, both in the discovery and validation cohorts. In addition, the time-dependent ROC curve analysis indicated that the seven-gene marker is better than serum alpha-fetoprotein in predicting 1-, 3-, and 5-year OS of HCC patients.

Research conclusions
--------------------

The seven-SAG signature was more applicable to evaluate OS of Asian HCC patients, which may provide new clinical evidence for the diagnosis and treatment of HCC transformed from cirrhosis.

Research perspectives
---------------------

The current study provides clues that the expression changes of senescence-associated gene are the molecular basis for the progression of cirrhosis to liver cancer. Finding effective senescence-associated molecular biomarkers and predictive features of HCC prognosis is necessary.
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